A new AI tool that models how variations in peptides change T cell receptor binding could help design immunotherapies with fewer off-target effects. Protein complexes that adorn the surface of T cells ...

The TCR repertoire provides a novel platform for investigating the modulation of the TME post-TACE and the underlying mechanisms governing tumor development and recurrence. Clarifying the distinctive ...

Chimeric antigen receptor (CAR)-T cells and T-cell therapies have been used in the treatment of various cancers for several years. In a review published in JAMA, a research team led by Christian ...

COLLEGE STATION, Texas--(BUSINESS WIRE)--Matica Biotechnology, a leading Texas-based viral vector Contract Development and Manufacturing Organization (CDMO), has announced a strategic partnership with ...

The gray portion of this schematic represents a nanodisc, where for the first time researchers were able to replicate the native membrane environment (red dots) of a T-cell receptor (cyan). One of the ...

Initial clinical data are anticipated from mid-2026.

California-based immunotherapy company 3T Biosciences has appointed Rebeca Villarreal-Barragan as head of clinical operations ...

The TIME trial: Phase II randomized controlled trial of time-of-day–specified immunotherapy for advanced melanoma. This is an ASCO Meeting Abstract from the 2025 ASCO Annual Meeting I. This abstract ...

Secondary primary malignancies (SPMs) with CAR-T cell therapy in RR-DLBCL from real-world data. This is an ASCO Meeting Abstract from the 2025 ASCO Annual Meeting I. This abstract does not include a ...